



PRODUCT: **Palynziq®**

COMPANY: BioMarin Pharmaceutical, Inc.

THERAPEUTIC AREA & INDICATION:

Lowers blood levels of phenylalanine, an amino acid that causes PKU (phenylketoneuria) leading to brain damage and seizures beginning in infancy

ABOUT THE PRODUCT

Palynziq is the first bacterially derived PEGylated enzyme therapy, indicated for eligible patients with phenylketonuria (PKU), a rare genetic disorder. Patients with PKU cannot metabolize phenylalanine (Phe), an amino acid that is neurotoxic at high levels, resulting in significant neurological deficits. To avoid these outcomes, PKU patients must restrict their diet, avoiding natural protein entirely. Palynziq reduces Phe levels to normal levels in many patients and within international guidelines in even greater numbers, while allowing some patients to eat a normal diet.